The life expectancy of patients with localized prostate cancer at treatment initiation has increased, and post-treatment quality of life has become a key issue. The aim of this study is to assess the impact of Radical prostatectomy (RP) on patients' sexual health and satisfaction according to sexual motivation using a self-administered questionnaire completed by two groups of RP patients, with high or lower levels of sexual motivation. A total of 63 consecutive patients were included (mean age, 63.9 years), of whom 74.6% were being treated for erectile dysfunction (ED). After RP, patients reported lower sexual desire (52.4%), reduced intercourse frequency (79.4%), anorgasmia (39.7%), less satisfying orgasm (38.1%), climacturia (25.4%), greater distress (68.3%) and/or lower partner satisfaction (56.5%). Among the most sexually motivated patients, 76.0% reported loss of masculine identity, 52% loss of self-esteem and 36.0% anxiety about performance. These rates were lower among less motivated patients (52.6, 28.9, and 18.4%, respectively). Mean overall satisfaction score was 4.8±2.9. The score was significantly lowered in motivated than less motivated patients (3.4 vs 5.8) (P ¼ 0.001). In conclusion, RP adversely affected erectile and orgasmic functions but also sexual desire, self-esteem and masculinity. The more motivated patients experienced greater distress and were less satisfied.
Introduction
Radical prostatectomy (RP) is a recommended standard treatment for patients with low or intermediate risk prostate cancer and a life expectancy of more than 10 years. With increasingly early diagnosis, life expectancy at treatment initiation has increased and post-treatment quality of life (QoL) has become a key issue in the choice of treatment. However, all treatments (RP, external beam radiotherapy, brachytherapy) adversely affect QoL. 1 The main side effects of RP are urinary incontinence and erectile dysfunction (ED), with ED having a possibly greater adverse impact on patients' QoL in the longer term than urinary disorders and the fear of relapse, especially in younger patients. 2 So far, most studies have focussed on ED rather than on the broader issue of quality of sex life. The urologist tends to focus on the mechanical rigidity of erections. Even so, according to a recent survey in France, only 38% of urologists routinely offer some form of pharmacological penile rehabilitation after RP, whereas 87% of the International Society for Sexual Medicine practitioners do so, with those managing over 50 RP patients per year being the most proactive. 3, 4 In addition, even if erections are restored after RP, with or without treatment, sexual bother increases after RP and sexual health most often does not return to its preoperative level. 5 The aim of this study is to assess the impact of RP on patients' sexual health and satisfaction according to sexual motivation.
Subjects and methods
We performed a review of the literature to identify the different domains relevant to male sexuality in order to devise a simple self-assessment sexual health questionnaire for patients who had undergone RP. The questionnaire was comprised of 16 items assessing erectile function, ED treatments, sexual desire, orgasm and the psychological impact of ED. Overall sexual satisfaction was assessed by a visual analog scale from 0 to 10 (0 ¼ not at all satisfied; 10 ¼ highly satisfied) (Supplementary Appendix 1).
Between January 2008 and July 2008, the questionnaire was administered to 64 consecutive patients during follow-up after RP. The patients completed the questionnaire in the waiting room before the start of the consultation. Demographic and clinical data were collected from their medical records. Institutional Review Board approval was obtained for the retrospective chart review.
We offer postoperative ED treatment to all RP patients who are sexually active preoperatively. 6 The issue of ED treatment is raised after surgery, once anxiety over surgery is over and patients have received reassurance about their cancer treatment. Some patients request sexual management promptly, others do not. Patients were thus arbitrarily divided into two groups according to whether they had expressed a clear demand for sexual management (Group 1: sexually motivated) or not (Group 2: less sexually motivated). The two groups were compared by Student's t test or Wilcoxon's test, as appropriate.
To study the influence of duration of postoperative care, we compared results for three time frames (o12, 12-24 and 424 months). We used chi-square statistics with or without Yate's correction for sexual health variables (loss of masculine identity, loss of self-esteem and anxiety over performance) and ANOVA for the sexual satisfaction score (after testing for the assumptions of normality and homogeneity of variance (Bartlett's test)).
Results

Patient characteristics
Data were available for 63 of the 64 patients as one patient refused to complete the questionnaire. The mean age of these 63 patients was 63.9±6.7 years. A total of 50 patients had undergone laparoscopic RP, 9 perineal RP, and 4 retropubic RP. No data were available for nerve sparing. The presence of cardiovascular risk factors was the main comorbidity (29 patients, 46%). The median interval between RP and administration of the questionnaire was 26.8 months (range, 6-67). Follow-up was less than 12 months in 9 patients, between 12 and 24 months in 24 patients and longer than 24 months in 30 patients. Nine patients had received adjuvant therapy after a mean delay of 21 months (8 external beam radiotherapy and 1 anti-androgen treatment). None had received neoadjuvant therapy. Prostate specific antigen was detectable in only three patients at the time of the study (0.1, 0.81 and 0.21 ng ml À1 ). Patient and tumor characteristics are given in Table 1 .
All 63 patients were heterosexual, with partners, and claimed to have had sexually satisfactory intercourse before surgery. Six reported moderate preoperative ED that had not, however, warranted pharmacological treatment. After surgery, 25 of the 63 patients had requested ED treatment before it was offered (Group 1-motivated to stay sexually active) (mean age, 65.3 years). The remaining 38 patients were in Group 2 (less motivated) (mean age, 63.0 years).
ED treatment
A total of 47 patients (74.6%) were being treated for ED at the time of the survey: 39 (82%) with intracavernous prostaglandin injections (ICI), 4 (9%) with an oral type-5 phosphodiesterase inhibitor (PDE5-I) and 4 (9%) with a penile prosthesis. In Group 1 (motivated), 21/25 (84%) were under treatment. The four other patients had refused the offer of ICI but were not taking a PDEI-5 because it was ineffective and/or too expensive. In Group 2 (less motivated), 26/38 patients (68.4%) had taken up the offer of ED treatment, four had sufficiently adequate erections not to require treatment, and eight had come to terms with their ED and were Sexual desire, frequency of intercourse and orgasm after RP Results are summarized in Table 2 . After RP, half of the patients reported a decrease in sexual desire and three quarters reported decreased frequency of intercourse, anorgasmia or a less satisfying orgasm. Before RP, all 63 patients had achieved orgasm (77.8% at each intercourse). Inadvertent urine leakage at orgasm (climacturia) was reported by 16 patients (25.4%) and considered to be bothersome by 9/16 patients (56.3%), but not to the extent of precluding intercourse. Four of the 16 patients who experienced climacturia were incontinent.
The absence of ejaculation was considered bothersome by 33/61 patients (54.1%) and bothersome enough to avoid intercourse by 5/61 patients (8.2%). Two patients did not answer this question.
Psychological impact
Overall, 43 patients (68.3%) experienced at least one of the following: loss of masculine identity (n ¼ 39, 61.9% of patients), loss of self-esteem (n ¼ 24, 38.1%) and anxiety over performance (n ¼ 16, 25.4%). The feeling of loss of masculine identity could be either overwhelming (10/39, 25.6%) or partial (29/39, 74.4%). The adverse psychological impact was greatest in Group 1 patients (Table 3 ) and did not depend on length of follow-up (Table 4) .
Overall sexual satisfaction
Mean sexual satisfaction score on the visual analog scale was 4.8 ± 2.9 (out of 10). Group 2 patients had a higher mean score than Group 1 patients; untreated Group 1 patients were less satisfied than treated patients; treated and untreated Group 2 patients had similar scores (Table 2) . Patients with a penile prosthesis had the highest mean score (8.1). The score did not depend on length of follow-up (Table 4) , patient age and tumor characteristics (Table 5) . Overall, 56.5% of patients claimed that their partner felt less sexual satisfaction since the operation had taken place.
Discussion
When advocating RP in young men with prostate cancer, simply focusing on ED, especially in those patients who most value their sexual activity, is not enough. Other important QoL sexual domains such as libido and orgasm need to be considered.
For a satisfactory sexual relationship, maintaining a sufficiently rigid erection is important. Early penile rehabilitation can significantly improve the rate of postoperative spontaneous erections and sexual QoL, and administration of a PDEI-5 such as sildenafil can help to enhance rigidity. [7] [8] [9] According to a literature review, the efficacy of sildenafil ranges from 14 to 53%, but this range can be extended to 14-85% on switching to ICI.
10,11 Penile rehabilitation should be discussed with all patients, regardless of their sexual motivation, and initiated promptly after RP.
9,12,13 Among our 63 RP patients, 74.6% were regularly using ED treatment and 81% had erections adequate for intercourse with or without pharmacological assistance. Most treated patients were using ICI (82%) for reasons of efficacy and cost despite a preference for less invasive treatment (French national health insurance reimburses ICI but not PDEI-5s). Most patients (70.2%) reported that they were satisfied with their ED treatment.
Despite their ED treatment, half of our patients experienced diminished sexual desire and three quarters less frequent intercourse after a median follow-up of 2 years. This agrees with published 
a Group 1 vs Group 2: P ¼ 0.001. b Untreated vs treated: Group 1: P ¼ 0.0117; Group 2: P ¼ 0.0884.
Sexual health after radical prostatectomy R Messaoudi et al decreased libido rates (45-55%) after RP. 14, 15 The decrease may be related to hypogonadonism and may be amenable to androgen replacement therapy in patients whose prostate cancer is under control. 16, 17 A prospective study found a high serum luteinizing hormone level and a decrease in serum dihydrotestosterone but none in total or free testosterone. 18 We did not perform any hormone assays to assess hypogonadism in our study.
Most of our patients experienced compromised orgasm (anorgasmia, 39.7%; less satisfying orgasm, 38.1%). This observation supports the results of a study in 239 RP patients showing a 37% prevalence of complete absence of orgasm, as well as of decreased orgasm intensity. 19 Orgasmic function improves linearly over the 48 months after RP but is not improved by IPDE-5 administration. 20 The physiology of orgasm has not yet been fully elucidated. Orgasm includes involuntary muscle contractions, contraction of the seminal vesicles and prostate, changes in heart and respiratory rates, and modified consciousness. After RP, the absence of a feeling of seminal vesicle and prostate contraction may account for less satisfying orgasms. In addition, some patients may be bothered by the absence of ejaculation (54.1% in our study). Among our patients, 8.2% avoided intercourse for this reason. It is therefore important to inform patients that the prostate and seminal vesicles are not required for orgasm, which can occur without ejaculation and/or with a flaccid penis. Patients should be counseled to persevere and prolong intercourse.
Urine leakage at orgasm might also explain less satisfying orgasms. This surgical complication has received little attention. A quarter of our patients suffered from climacturia and over half of these found it bothersome. Climacturia was first reported by Koeman et al.
15 who recorded a high 64% incidence among 20 sexually active RP patients. Later studies give lower rates, namely, 20.2% among 475 RP or cystectomy patients (with a lower rate for cystectomy) and 45% among 42 RP patients. 21, 22 Of these patients, 48% found it bothersome. 22 Climacturia can often be associated with moderate stress incontinence 23 but this was the case in only 4 of our 16 patients. Impaired sphincter function was therefore not the cause of the climacturia in most of our patients. A possible cause might be lack of sphincter smooth muscle tissue associated with normal relaxation of the external sphincter at orgasm. 15 But data on climacturia as a function of bladder neck preservation during RP are lacking. Recommended management is emptying the bladder before intercourse and/or use of a condom, or possibly pelvic floor rehabilitation treatment. 24 Studies of tricyclic antidepressant administration and penis rings are anecdotal.
Compromised sexual function had a strong psychological and emotional impact on our patient. This impact was greater in the more sexually motivated patients. Two-thirds of patients experienced at least one of the following: loss of masculine identity, loss of self-esteem and anxiety over performance. Loss of masculine identity affected Sexual health after radical prostatectomy R Messaoudi et al the most patients (61.9%) and has been frequently reported in the literature. 25 It can affect everyday relationships with women, sexual intimacy and fantasy life. 26 Loss of self-esteem was experienced by 28.9% of the less motivated patients and 52% of the motivated patients, and anxiety over performance before intercourse by 25.4% of all patients. These rates are somewhat lower than published rates (75% for self-esteem, 25 28-70% for anxiety over performance 27 ). The psychological impact of compromised sexual function did not depend on the time-frame of follow-up after RP (o12, 12-24, 424 months), confirming the difficulty patients have in coping psychologically with continued compromised sexual function. Erections may improve, but sexual bother tends to worsen or remain stable during the 24 months after RP. 5 To improve patients' and their partners' sex-lives, it is thus necessary not only to treat the mechanics (ED treatment), but also to provide appropriate psychological or sexual counseling to help cope with the impact of RP on sexual desire and orgasm. 6, 28 In our study, the patients who were most motivated to remain sexually active after RP (Group 1) experienced a greater degree of bother and had a lower overall sexual satisfaction score than the less motivated patients. Their satisfaction score was very low (0.5/10) when they were not receiving ED treatment but higher on treatment (3.9/10), thus confirming the benefit of treatment in motivated patients. 29 The benefit of ED treatment on satisfaction was not apparent in the less motivated patients. These patients had a higher satisfaction score than motivated patients and their score did not depend on treatment (6.9 vs 5.3; P ¼ 0.088). Untreated less motivated patients (12.7%) did not find the absence of an erection as bothersome. Despite the lack of ED treatment, they had a satisfying sex-life with physical intimacy not involving intercourse. A 50% rate of indifference to ED has been reported among prostate cancer survivors. 30 Patients' attitude to their sex-life is thus a key factor to be taken into account when choosing treatment for localized prostate cancer. The most motivated to maintain erections are the most difficult to satisfy. If RP is indicated, patients should be provided with full information on repercussions on sexual health and undergo close postoperative follow up to reduce distress and improve QoL.
Our prospective study has several limitations: a small sample size, a cross-sectional and not longitudinal design, no preoperative baseline (we had to rely on patients' recall of their earlier sexuality), lack of data on nerve-sparing surgery and use of unvalidated psychometric instruments. We devised our own questionnaire for sexual health because available validated questionnaires omit key items in our study (eg, climacturia and lack of ejaculation), if they are simple and easy-to-use, or if they do contain these items, they are too complex for daily clinical use. Our questionnaire also had the advantage of enabling comparison between two groups of patients with different expectations with regard to their sexuality.
Conclusion
Postoperative management of the sexual health of RP patients should consider not only the mechanics of erections but also aspects such as sexual desire, orgasm, climacturia and the psychological impact of compromised sexuality (loss of masculine identity, loss of self-esteem and anxiety about performance). Adverse repercussions engendered greater distress in sexually more motivated patients, even if their ED treatment was seen to be satisfactory, than in less motivated patients whose sex-life proved to be more satisfying despite ED. The urologist should bring up the issues of ED and other aspects of sexual dysfunction when treatment options for localized prostate cancer are being reviewed with the patient. Further studies on a larger population are needed to confirm our results.
